Australia's Chimeric Therapeutics leaps on positive FDA feedback for cancer therapy

Chimeric Therapeutics

21/03/2023 02:26

** Shares of Chimeric Therapeutics  CHM.AX  leap as much as
5.4% to A$0.059, posting their biggest intraday pct gain since
March 9
    ** Co says it got positive feedback from the U.S. Food and
Drug Administration (FDA) in a pre-Investigational New Drug
(IND) meeting about its cancer therapy CHM 2101
    ** Adds the feedback is a "significant milestone" towards an
IND application and Phase I clinical trial 
    ** As of last close, CHM down 30% YTD

 (Reporting by Harshita Swaminathan)
 ((Harshita.Swaminathan@thomsonreuters.com))